Dopamine partial agonists: a discrete class of antipsychotics

References

• Accord Healthcare Limited (2021). Olanzapine 10 mg Film-coated Tablets. https://www.medicines.org.uk/emc/product/6082
   Google Scholar
• Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. PLoS One, 16(9), e0257129. doi:10.1371/journal.pone.0257129
   PubMed Web of Science ®Google Scholar
• Allen, K., Baban, A., Munjiza, J., & Pappa, S. (2019). Management of Antipsychotic-Related Sexual Dysfunction: systematic Review. The Journal of Sexual Medicine, 16(12), 1978–1987. doi:10.1016/j.jsxm.2019.08.022
   PubMed Web of Science ®Google Scholar
• Amada, N., Akazawa, H., Ohgi, Y., Maeda, K., Sugino, H., Kurahashi, N., Kikuchi, T., & Futamura, T. (2019). Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5-HT(2A) receptors in rats. Neuropsychopharmacology Reports, 39(4), 279–288. doi:10.1002/npr2.12076
   PubMedGoogle Scholar
• Barnes, T. R. (2003). The Barnes Akathisia Rating Scale–revisited. Journal of Psychopharmacology (Oxford, England), 17(4), 365–370. doi:10.1177/0269881103174013
   PubMed Web of Science ®Google Scholar
• Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 19(3), 295–314. doi:10.1080/14740338.2020.1713091
   PubMed Web of Science ®Google Scholar
• Beach, S. R., Celano, C. M., Sugrue, A. M., Adams, C., Ackerman, M. J., Noseworthy, P. A., & Huffman, J. C. (2018). QT Prolongation, Torsades de Pointes, and Psychotropic Medications: a 5-Year Update. Psychosomatics, 59(2), 105–122. doi:10.1016/j.psym.2017.10.009
   PubMed Web of Science ®Google Scholar
• Berardis, D. D., Rapini, G., Olivieri, L., Giardini, A., Lauretis, I. D., Serroni, N., Orsolini, L., Fornaro, M., Iasevoli, F., Trotta, S., Cottura, P., Vellante, F., Alessandrini, M., & Giannantonio, M. D. (2021). Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology, 19(1), 174–178. doi:10.9758/cpn.2021.19.1.174
   PubMed Web of Science ®Google Scholar
• Besag, F. M. C., Vasey, M. J., & Salim, I. (2021). Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review. CNS Drugs, 35(5), 507–526. Maydoi:10.1007/s40263-021-00812-1
   PubMed Web of Science ®Google Scholar
• Bleakley, S., Olofinjana, O., & Taylor, D. (2007). Which antipsychotics would mental health professionals take themselves? Psychiatric Bulletin, 31(3), 94–96. doi:10.1192/pb.bp.106.012955
   Google Scholar
• Bourin, M., & Briley, M. (2004). Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs. Human Psychopharmacology, 19(2), 135–139. doi:10.1002/hup.561
   PubMed Web of Science ®Google Scholar
• Brissos, S., & Taylor, D. (2022). Weekly Supervised Administration of Oral Antipsychotics: an Alternative to Long-Acting Injections? CNS Drugs, 36(4), 315–325. doi:10.1007/s40263-022-00906-4
   PubMed Web of Science ®Google Scholar
• Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018). Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry: official Journal of the World Psychiatric Association (WPA), 17(3), 330–340. doi:10.1002/wps.20579
   PubMed Web of Science ®Google Scholar
• Carlsson, A. (1983). Dopamine receptor agonists: intrinsic activity vs. state of receptor. Journal of Neural Transmission, 57(4), 309–315. doi:10.1007/BF01249001
   PubMed Web of Science ®Google Scholar
• Casey, D. E., Carson, W. H., Saha, A. R., Liebeskind, A., Ali, M. W., Jody, D., & Ingenito, G. G, Aripiprazole Study Group (2003). Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology, 166(4), 391–399. 4/2003 doi:10.1007/s00213-002-1344-3
   PubMed Web of Science ®Google Scholar
• Chouinard, G., Jones, B. D., & Annable, L. (1978). Neuroleptic-induced supersensitivity psychosis. The American Journal of Psychiatry, 135(11), 1409–1410. doi:10.1176/ajp.135.11.1409
   PubMed Web of Science ®Google Scholar
• Citrome, L. (2015). The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International Journal of Clinical Practice, 69(11), 1211–1220. doi:10.1111/ijcp.12752
   PubMed Web of Science ®Google Scholar
• Citrome, L. (2018). Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment, 14, 2563–2577. doi:10.2147/NDT.S159704
   PubMed Web of Science ®Google Scholar
• Corponi, F., Fabbri, C., Bitter, I., Montgomery, S., Vieta, E., Kasper, S., Pallanti, S., & Serretti, A. (2019). Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology, 29(9), 971–985. doi:10.1016/j.euroneuro.2019.06.008
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Jain, R., Meyer, J. M., Periclou, A., Carrothers, T., Barabássy, Á., Patel, M., & Earley, W. (2019). Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment, 15, 2537–2550. doi:10.2147/NDT.S210340
   PubMed Web of Science ®Google Scholar
• Crapanzano, C., Damiani, S., & Guiot, C. (2021). Quetiapine in the Anxiety Dimension of Mood Disorders: a Systematic Review of the Literature to Support Clinical Practice. Journal of Clinical Psychopharmacology, 41(4), 436–449. doi:10.1097/JCP.0000000000001420
   PubMed Web of Science ®Google Scholar
• Crawford, M. J., Thana, L., Evans, R., Carne, A., O'Connell, L., Claringbold, A., Saravanamuthu, A., Case, R., Munjiza, J., Jayacodi, S., Reilly, J. G., Hughes, E., Hoare, Z., Barrett, B., Leeson, V. C., Paton, C., Keown, P., Pappa, S., Green, C., & Barnes, T. R. (2020). Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. Health Technology Assessment (Winchester, England), 24(44), 1–54. doi:10.3310/hta24440
   Web of Science ®Google Scholar
• Culpepper, L., Vieta, E., Kelly, D. L., Patel, M. D., Szatmári, B., Hankinson, A., & Earley, W. R. (2022). Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatric Disease and Treatment, 18, 995–1011. doi:10.2147/NDT.S348143
   PubMed Web of Science ®Google Scholar
• DE Hert, M., Correll, C. U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, J., Gautam, S., Möller, H.-J., Ndetei, D. M., Newcomer, J. W., Uwakwe, R., & Leucht, S. (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry : official Journal of the World Psychiatric Association (WPA), 10(1), 52–77. doi:10.1002/j.2051-5545.2011.tb00014.x
   PubMed Web of Science ®Google Scholar
• De Hert, M., Detraux, J., & Stubbs, B. (2016). Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opinion on Drug Safety, 15(6), 809–823. doi:10.1517/14740338.2016.1167873
   PubMed Web of Science ®Google Scholar
• De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2011). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews. Endocrinology, 8(2), 114–126. doi:10.1038/nrendo.2011.156
   PubMed Web of Science ®Google Scholar
• De Hert, M., Peuskens, J., Sabbe, T., Mitchell, A. J., Stubbs, B., Neven, P., Wildiers, H., & Detraux, J. (2016). Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatrica Scandinavica, 133(1), 5–22. doi:10.1111/acps.12459
   PubMed Web of Science ®Google Scholar
• Dibonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012). A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry, 12, 20. Mar 20doi:10.1186/1471-244X-12-20
   PubMed Web of Science ®Google Scholar
• Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, 656370. doi:10.1155/2014/656370
   PubMed Web of Science ®Google Scholar
• Enders, J. R., Reddy, S. G., Strickland, E. C., & McIntire, G. L. (2017). Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance. Clinical Mass Spectrometry, 6, 21–24. doi:10.1016/j.clinms.2017.11.001
   Google Scholar
• Fleischhacker, W., Galderisi, S., Laszlovszky, I., Szatmári, B., Barabássy, Á., Acsai, K., Szalai, E., Harsányi, J., Earley, W., Patel, M., & Németh, G. (2019). The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry : The Journal of the Association of European Psychiatrists, 58, 1–9. Maydoi:10.1016/j.eurpsy.2019.01.015
   PubMed Web of Science ®Google Scholar
• Frankel, J. S., & Schwartz, T. L. (2017). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology, 7(1), 29–41. doi:10.1177/2045125316672136
   PubMed Web of Science ®Google Scholar
• Fusaroli, M., Raschi, E., Giunchi, V., Menchetti, M., Rimondini Giorgini, R., De Ponti, F., et al. (2022). Impulse Control Disorders by Dopamine Partial Agonists: a Pharmacovigilance-Pharmacodynamic Assessment through the FDA Adverse Event Reporting System. International Journal of Neuropsychopharmacology, 25(9), 727–736. doi:10.1093/ijnp/pyac031
   PubMed Web of Science ®Google Scholar
• Ginovart, N., & Kapur, S. (2012). Role of Dopamine D2 Receptors for Antipsychotic Activity. In: gross G, Geyer MA, editors. Current Antipsychotics. Heidelberg, Germany: Springer Verlag GmbH. p. 27–52.
   Google Scholar
• Girgis, R. R., Forbes, A., Abi-Dargham, A., & Slifstein, M. (2020). A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology: official Publication of the American College of Neuropsychopharmacology, 45(5), 786–792. doi:10.1038/s41386-019-0590-6
   PubMed Web of Science ®Google Scholar
• Girgis, R. R., Slifstein, M., D'Souza, D., Lee, Y., Periclou, A., Ghahramani, P., Laszlovszky, I., Durgam, S., Adham, N., Nabulsi, N., Huang, Y., Carson, R. E., Kiss, B., Kapás, M., Abi-Dargham, A., & Rakhit, A. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology, 233(19-20), 3503–3512. doi:10.1007/s00213-016-4382-y
   PubMed Web of Science ®Google Scholar
• Grunder, G., Carlsson, A., & Wong, D. F. (2003). Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of General Psychiatry, 60(10), 974–977. doi:10.1001/archpsyc.60.10.974
   PubMed Web of Science ®Google Scholar
• Haddad, P. M., Brain, C., & Scott, J. (2014). Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures, 5, 43–62. doi:10.2147/PROM.S42735
   PubMedGoogle Scholar
• Hart, X. M., Schmitz, C. N., & Gründer, G. (2022). Molecular Imaging of Dopamine Partial Agonists in Humans: implications for Clinical Practice. Frontiers in Psychiatry, 13, 832209. doi:10.3389/fpsyt.2022.832209
   PubMed Web of Science ®Google Scholar
• Hasan, A., Falkai, P., Lehmann, I., & Gaebel, W. (2020). Schizophrenia. Deutsches Arzteblatt International, 117(24), 412–419. doi:10.3238/arztebl.2020.0412
   PubMed Web of Science ®Google Scholar
• Hjorth, S. (2021). The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. Frontiers in Psychiatry, 12, 760181. 2021-November-24;doi:10.3389/fpsyt.2021.760181
   PubMed Web of Science ®Google Scholar
• Holt, R. I., & Peveler, R. C. (2011). Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology, 74(2), 141–147. doi:10.1111/j.1365-2265.2010.03814.x
   PubMed Web of Science ®Google Scholar
• Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin, 47(4), 1116–1129. doi:10.1093/schbul/sbab017
   PubMed Web of Science ®Google Scholar
• Horowitz, M. A., Murray, R. M., & Taylor, D. (2021). Tapering Antipsychotic Treatment. JAMA Psychiatry, 78(2), 125–126. doi:10.1001/jamapsychiatry.2020.2166
   PubMed Web of Science ®Google Scholar
• Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 394(10202), 939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Ishigooka, J., Iwashita, S., Higashi, K., Liew, E. L., & Tadori, Y. (2018). Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia. Journal of Clinical Pharmacology, 58(1), 74–80. doi:10.1002/jcph.979
   PubMed Web of Science ®Google Scholar
• Jauhar, S., Guloksuz, S., Andlauer, O., Lydall, G., Marques, J. G., Mendonca, L., Dumitrescu, I., Roventa, C., De Vriendt, N., Van Zanten, J., Riese, F., Nwachukwu, I., Nawka, A., Psaras, R., Masson, N., Krishnadas, R., & Volpe, U., European Federation of Psychiatric Trainees’ Research Group (2012). Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry, 12, 27. doi:10.1186/1471-244X-12-27
   PubMed Web of Science ®Google Scholar
• Javed, A., Arthur, H., Curtis, L., Hansen, L., & Pappa, S. (2019). Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy, 8(2), 215–230. doi:10.1007/s40120-019-0138-z
   PubMed Web of Science ®Google Scholar
• Jindal, K. C., Singh, G. P., & Munjal, V. (2013). Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. International Journal of Psychiatry in Clinical Practice, 17(1), 21–29. doi:10.3109/13651501.2011.653376
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Osuntokun, O., Kryzhanovskaya, L. A., Xu, W., Stauffer, V. L., Watson, S. B., & Breier, A. (2009). A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of Clinical Psychiatry, 70(4), 572–581. 4/2009doi:10.4088/jcp.08m04421
   PubMed Web of Science ®Google Scholar
• Kane, J. M., Sanchez, R., Zhao, J., Duca, A. R., Johnson, B. R., McQuade, R. D., Eramo, A., Baker, R. A., & Peters-Strickland, T. (2013). Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics, 16(7), 917–925. doi:10.3111/13696998.2013.804411
   PubMedGoogle Scholar
• Kapur, S., & Remington, G. (2001). Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry, 50(11), 873–883. doi:10.1016/S0006-3223(01)01251-3
   PubMed Web of Science ®Google Scholar
• Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. The American Journal of Psychiatry, 157(4), 514–520. 4/2000doi:10.1176/appi.ajp.157.4.514
   PubMed Web of Science ®Google Scholar
• Kasper, S., & Resinger, E. (2003). Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology, 28(Suppl 1), 27–38. doi:10.1016/S0306-4530(02)00115-4
   PubMedGoogle Scholar
• Keks, N., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. (2020). Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs, 34(5), 473–507. doi:10.1007/s40263-020-00718-4
   PubMed Web of Science ®Google Scholar
• Kessler, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B., & Meltzer, H. Y. (2006). Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology: official Publication of the American College of Neuropsychopharmacology, 31(9), 1991–2001. doi:10.1038/sj.npp.1301108
   PubMed Web of Science ®Google Scholar
• Khandaker, G. M., Barnett, J. H., White, I. R., & Jones, P. B. (2011). A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophrenia Research, 132(2-3), 220–227. doi:10.1016/j.schres.2011.06.017
   PubMed Web of Science ®Google Scholar
• Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021). Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports, 41(2), 134–143. doi:10.1002/npr2.12180
   PubMed Web of Science ®Google Scholar
• Kim, D. D., Barr, A. M., Lian, L., Yuen, J. W. Y., Fredrikson, D., Honer, W. G., Thornton, A. E., & Procyshyn, R. M. (2021). Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early course of schizophrenia: a systematic review and meta-analysis. NPJ Schizophrenia, 7(1), 29. doi:10.1038/s41537-021-00158-z
   PubMed Web of Science ®Google Scholar
• Kim, H. K., Leonard, J. B., Corwell, B. N., & Connors, N. J. (2021). Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium. Expert Opinion on Drug Safety, 20(2), 123–138. doi:10.1080/14740338.2021.1865911
   PubMed Web of Science ®Google Scholar
• Kim, S., Solari, H., Weiden, P. J., & Bishop, J. R. (2012). Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Preference and Adherence, 6, 533–545.
   PubMed Web of Science ®Google Scholar
• Kirino, E. (2017). Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Annals of General Psychiatry, 16, 43. doi:10.1186/s12991-017-0166-y
   PubMed Web of Science ®Google Scholar
• Kiss, B., Horváth, A., Némethy, Z., Schmidt, E., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., Agai-Csongor, E., Domány, G., Tihanyi, K., Adham, N., & Szombathelyi, Z. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. The Journal of Pharmacology and Experimental Therapeutics, 333(1), 328–340. doi:10.1124/jpet.109.160432
   PubMed Web of Science ®Google Scholar
• Kiss, B., Némethy, Z., Fazekas, K., Kurkó, D., Gyertyán, I., Sághy, K., Laszlovszky, I., Farkas, B., Kirschner, N., Bolf-Terjéki, E., Balázs, O., & Lendvai, B. (2019). Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Drug Design, Development and Therapy, 13, 3229–3248. doi:10.2147/DDDT.S188760
   PubMed Web of Science ®Google Scholar
• Lambert, M., Schimmelmann, B. G., Karow, A., & Naber, D. (2003). Subjective well-being and initial dysphoric reaction under antipsychotic drugs – concepts, measurement and clinical relevance. Pharmacopsychiatry, 36(Suppl 3), S181–S90. Nov
   PubMed Web of Science ®Google Scholar
• Lataster, J., van Os, J., de Haan, L., Thewissen, V., Bak, M., Lataster, T., Lardinois, M., Delespaul, P. A. G. E., & Myin-Germeys, I. (2011). Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. The Journal of Clinical Psychiatry, 72(10), 1397–1404. doi:10.4088/JCP.09m05466yel
   PubMed Web of Science ®Google Scholar
• Leucht, C., Kitzmantel, M., Chua, L., Kane, J., & Leucht, S, Cochrane Schizophrenia Group (2008). Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews, 23(1), Cd004278. doi:10.1002/14651858.CD004278.pub2
   Google Scholar
• Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., Geddes, J. R., Salanti, G., & Davis, J. M. (2017). Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. The American Journal of Psychiatry, 174(10), 927–942. doi:10.1176/appi.ajp.2017.16121358
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A. (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 18(4), 251–267. doi:10.2165/00023210-200418040-00005
   PubMed Web of Science ®Google Scholar
• Lippi, M., Fanelli, G., Fabbri, C., De Ronchi, D., & Serretti, A. (2022). The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? International Clinical Psychopharmacology, 37(6), 263–275. /YIC.0000000000000417. doi:10.1097/YIC.0000000000000417
   PubMed Web of Science ®Google Scholar
• Mailman, R. B., & Murthy, V. (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Current Pharmaceutical Design, 16(5), 488–501. doi:10.2174/138161210790361461
   PubMed Web of Science ®Google Scholar
• Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014). Clinical pharmacology of atypical antipsychotics: an update. EXCLI Journal, 13, 1163–1191. 10/13
   PubMed Web of Science ®Google Scholar
• McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine, 2(1), 13. 2004/04/28doi:10.1186/1741-7015-2-13
   PubMedGoogle Scholar
• McIntyre, R. S., Daniel, D. G., Vieta, E., Laszlovszky, I., Goetghebeur, P. J., Earley, W. R., & Patel, M. D. (2022). The Efficacy of Cariprazine on Cognition: a Post Hoc Analysis From Phase II/III Clinical Trials in Bipolar Mania, Bipolar Depression, and Schizophrenia. CNS Spectrums, 1–12. doi:10.1017/S109285292200013X
   Web of Science ®Google Scholar
• Meltzer, H. Y., & Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin, 2(1), 19–76. doi:10.1093/schbul/2.1.19
   PubMed Web of Science ®Google Scholar
• Mir, A., Shivakumar, K., Williamson, R. J., McAllister, V., O'Keane, V., & Aitchison, K. J. (2008). Change in sexual dysfunction with aripiprazole: a switching or add-on study. Journal of Psychopharmacology (Oxford, England), 22(3), 244–253. 5/1/2008doi:10.1177/0269881107082901
   PubMed Web of Science ®Google Scholar
• Mizrahi, R., Rusjan, P., Agid, O., Graff, A., Mamo, D. C., Zipursky, R. B., & Kapur, S. (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. The American Journal of Psychiatry, 164(4), 630–637. doi:10.1176/ajp.2007.164.4.630
   PubMed Web of Science ®Google Scholar
• Mohr, P., Masopust, J., & Kopeček, M. (2021). Dopamine Receptor Partial Agonists: do They Differ in Their Clinical Efficacy? Frontiers in Psychiatry, 12, 781946.
   PubMed Web of Science ®Google Scholar
• Montastruc, F., Nie, R., Loo, S., Rej, S., Dell’Aniello, S., Micallef, J., Suissa, S., & Renoux, C. (2019). Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry, 76(4), 409–417. doi:10.1001/jamapsychiatry.2018.4149
   PubMed Web of Science ®Google Scholar
• Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617–622.
   PubMed Web of Science ®Google Scholar
• Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016). Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry : The Journal of Mental Science, 209(5), 361–365. doi:10.1192/bjp.bp.116.182683
   PubMed Web of Science ®Google Scholar
• Mylan (2022). Summary of Product Characteristics. Quetiapine 300 mg film-coated tablets. https://www.medicines.org.uk/emc/product/8252/smpc#gref;
   Google Scholar
• Naber, D., Hansen, K., Forray, C., Baker, R. A., Sapin, C., Beillat, M., Peters-Strickland, T., Nylander, A.-G., Hertel, P., Andersen, H. S., Eramo, A., Loze, J.-Y., & Potkin, S. G. (2015). Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research, 168(1-2), 498–504. doi:10.1016/j.schres.2015.07.007
   PubMed Web of Science ®Google Scholar
• Natesan, S., Reckless, G. E., Barlow, K. B. L., Nobrega, J. N., & Kapur, S. (2011). Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models. The International Journal of Neuropsychopharmacology, 14(9), 1165–1178. doi:10.1017/S1461145710001343
   PubMed Web of Science ®Google Scholar
• Németh, B., Molnár, A., Akehurst, R., Horváth, M., Kóczián, K., Németh, G., Götze, Á., & Vokó, Z. (2017). Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. Journal of Comparative Effectiveness Research, 6(8), 639–648. doi:10.2217/cer-2017-0024
   PubMed Web of Science ®Google Scholar
• Németh, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmári, B., Harsányi, J., Barabássy, Á., Debelle, M., Durgam, S., Bitter, I., Marder, S., & Fleischhacker, W. W. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England), 389(10074), 1103–1113. doi:10.1016/S0140-6736(17)30060-0
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi, A. (2010). The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Current Opinion in Investigational Drugs (London, England : 2000), 11(7), 802–812.
   PubMed Web of Science ®Google Scholar
• Novick, D., Haro, J. M., Bertsch, J., & Haddad, P. M. (2010). Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: thirty-Six-Month Results From the European Schizophrenia Outpatient Health Outcomes Study. Journal of Clinical Psychopharmacology, 30(5), 531–540. doi:10.1097/JCP.0b013e3181f14098
   PubMed Web of Science ®Google Scholar
• Oloyede, E., Clark, I., Mace, S., Whiskey, E., & Taylor, D. (2022). Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic Advances in Psychopharmacology, 12, 20451253211066642. doi:10.1177/20451253211066642
   Web of Science ®Google Scholar
• Orsolini, L., Bellagamba, S., Salvi, V., & Volpe, U. (2022). A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. Asian Journal of Psychiatry, 72, 103121. doi:10.1016/j.ajp.2022.103121
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Co.Ltd. (2020). Highlights of Prescribing Information, Rexulto (brexpiprazole) tablets for oral use. https://otsuka-us.com/sites/g/files/qhldwo2286/files/media/Rexulti-PI.pdf
   Google Scholar
• Otsuka Pharmaceutical Netherlands B.V. Summary of Product Characteristics (2018). RXULTI 0.25 mg film-coated tablets (brexpiprazole). https://www.ema.europa.eu/en/documents/product-information/rxulti-epar-product-information_en.pdf#:∼:text=The%20recommended%20starting%20dose%20for%20brexpiprazole%20is%201,and%20then%20to%204%20mg%20on%20day%208.?msclkid=41bfe1f3b01711ec9c8e0de528ca2bae;
   Google Scholar
• Pagsberg, A. K., Jeppesen, P., Klauber, D. G., Jensen, K. G., Rudå, D., Stentebjerg-Olesen, M., Jantzen, P., Rasmussen, S., Saldeen, E. A.-S., Lauritsen, M.-B G., Bilenberg, N., Stenstrøm, A. D., Nyvang, L., Madsen, S., Werge, T. M., Lange, T., Gluud, C., Skoog, M., Winkel, P., … Fink-Jensen, A. (2017). Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. The Lancet. Psychiatry, 4(8), 605–618. doi:10.1016/S2215-0366(17)30166-9
   PubMed Web of Science ®Google Scholar
• Pappa, S., Barnett, J., Gomme, S., Iliopoulou, A., Moore, I., Whitaker, M., McGrath, J., & Sie, M. (2021). Shared and Supported Decision Making in Medication in a Mental Health Setting: how Far Have We Come? Community Mental Health Journal, 57(8), 1566–1578. doi:10.1007/s10597-021-00780-2
   PubMed Web of Science ®Google Scholar
• Peciña, M., Sikora, M., Avery, E. T., Heffernan, J., Peciña, S., Mickey, B. J., & Zubieta, J.-K. (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: implications for anhedonia, anxiety and treatment response. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology, 27(10), 977–986. doi:10.1016/j.euroneuro.2017.08.427
   PubMed Web of Science ®Google Scholar
• Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T., Härkänen, T., Koskinen, S., & Lönnqvist, J. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64(1), 19–28. doi:10.1001/archpsyc.64.1.19
   PubMed Web of Science ®Google Scholar
• Periclou, A., Phillips, L., Ghahramani, P., Kapás, M., Carrothers, T., & Khariton, T. (2021). Population Pharmacokinetics of Cariprazine and its Major Metabolites. European Journal of Drug Metabolism and Pharmacokinetics, 46(1), 53–69. doi:10.1007/s13318-020-00650-4
   PubMed Web of Science ®Google Scholar
• Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet. Psychiatry, 7(1), 64–77. doi:10.1016/S2215-0366(19)30416-X
   PubMed Web of Science ®Google Scholar
• Plana-Ripoll, O., Pedersen, C. B., Agerbo, E., Holtz, Y., Erlangsen, A., Canudas-Romo, V., Andersen, P. K., Charlson, F. J., Christensen, M. K., Erskine, H. E., Ferrari, A. J., Iburg, K. M., Momen, N., Mortensen, P. B., Nordentoft, M., Santomauro, D. F., Scott, J. G., Whiteford, H. A., Weye, N., McGrath, J. J., & Laursen, T. M. (2019). A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet (London, England), 394(10211), 1827–1835. doi:10.1016/S0140-6736(19)32316-5
   PubMed Web of Science ®Google Scholar
• Polcwiartek, C., Kragholm, K., Hansen, S. M., Atwater, B. D., Friedman, D. J., Barcella, C. A., Graff, C., Nielsen, J. B., Pietersen, A., Nielsen, J., Søgaard, P., Torp-Pedersen, C., & Jensen, S. E. (2020). Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia. Schizophrenia Bulletin, 46(2), 354–362.
   PubMed Web of Science ®Google Scholar
• Procyshyn, R., Bezchlibnyk-Butler, K., & Jeffries, J. (2019). Clinical handbook of psychotropic drugs. (23rd rev. ed.). Cambridge, MA: Hogrefe & Huber Publishers.
   Google Scholar
• Raj, R., & Sidhu, B. S. (2008). Hyperprolactinaemia with amisulpride. Indian Journal of Psychiatry, 50(1), 54–56. doi:10.4103/0019-5545.39761
   PubMedGoogle Scholar
• Rancans, E., Dombi, Z. B., Mátrai, P., Barabássy, Á., Sebe, B., Skrivele, I., & Németh, G. (2021). The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. International Clinical Psychopharmacology, 36(3), 154–161. doi:10.1097/YIC.0000000000000351
   PubMed Web of Science ®Google Scholar
• Recordati Pharmaceuticals Limited (2022). Summary of Product Characteristics. Reagila 1.5mg hard capsules. https://www.medicines.org.uk/emc/product/9401/smpc?msclkid=c555d4fbb01611ecb52bf65c31760ff9;
   Google Scholar
• Rehse, M., Bartolovic, M., Baum, K., Richter, D., Weisbrod, M., & Roesch-Ely, D. (2016). Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia. Schizophrenia Research and Treatment, 2016, 8213165. doi:10.1155/2016/8213165
   PubMedGoogle Scholar
• Remington, G., & Kapur, S. (2010). Antipsychotic dosing: how much but also how often? Schizophrenia Bulletin, 36(5), 900–903. 9/2010doi:10.1093/schbul/sbq083
   PubMed Web of Science ®Google Scholar
• Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017). Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 62(9), 604–616. doi:10.1177/0706743717720448
   PubMed Web of Science ®Google Scholar
• Reynolds, G. P., & Czudek, C. (1995). New approaches to the drug treatment of schizophrenia. Adv Pharmacol, 32, 461–503. doi:10.1016/S1054-3589(08)61020-0
   PubMedGoogle Scholar
• Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. The American Journal of Psychiatry, 161(3), 473–479. doi:10.1176/appi.ajp.161.3.473
   PubMed Web of Science ®Google Scholar
• Saeedi, H., Remington, G., & Christensen, B. K. (2006). Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophrenia Research, 85(1-3), 222–231. doi:10.1016/j.schres.2006.03.033
   PubMed Web of Science ®Google Scholar
• Seeman, P. (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clinical Schizophrenia & Related Psychoses, 4(1), 56–73. doi:10.3371/CSRP.4.1.5
   PubMedGoogle Scholar
• Servonnet, A., Uchida, H., & Samaha, A. N. (2021). Continuous versus extended antipsychotic dosing in schizophrenia: less is more. Behavioural Brain Research, 401, 113076. doi:10.1016/j.bbr.2020.113076
   PubMed Web of Science ®Google Scholar
• Sher, L., & Kahn, R. S. (2019). Family interventions and prevention of suicide in first-episode schizophrenia. Acta Psychiatrica Scandinavica, 139(5), 484. doi:10.1111/acps.13018
   PubMed Web of Science ®Google Scholar
• Siafis, S., Tzachanis, D., Samara, M., & Papazisis, G. (2018). Antipsychotic Drugs: from Receptor-binding Profiles to Metabolic Side Effects. Current Neuropharmacology, 16(8), 1210–1223. doi:10.2174/1570159X15666170630163616
   PubMed Web of Science ®Google Scholar
• Simon, G. E., Stewart, C., Yarborough, B. J., Lynch, F., Coleman, K. J., Beck, A., Operskalski, B. H., Penfold, R. B., & Hunkeler, E. M. (2018). Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. JAMA Psychiatry, 75(3), 254–260. doi:10.1001/jamapsychiatry.2017.4437
   PubMed Web of Science ®Google Scholar
• Stahl, S. (2013). Stahl’s Essential Psychopharmacology. 4th ed. Cambridge, UK: Cambridge University Press.
   Google Scholar
• Stollberger, C., Huber, J. O., & Finsterer, J. (2005). Antipsychotic drugs and QT prolongation. International Clinical Psychopharmacology, 20(5), 243–251. 9/2005doi:10.1097/01.yic.0000166405.49473.70
   PubMed Web of Science ®Google Scholar
• Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., & Lieberman, J. A, Schizophrenia Trials Network (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry, 168(9), 947–956. doi:10.1176/appi.ajp.2011.10111609
   PubMed Web of Science ®Google Scholar
• Suzuki, H., Gen, K., & Inoue, Y. (2013). Comparison of the anti-dopamine D2 and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. Journal of Psychopharmacology (Oxford, England), 27(4), 396–400. doi:10.1177/0269881113478281
   PubMed Web of Science ®Google Scholar
• Swainston Harrison, T., & Perry, C. M. (2004). Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 64(15), 1715–1736. doi:10.2165/00003495-200464150-00010
   PubMed Web of Science ®Google Scholar
• Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012). Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophrenia Bulletin, 38(5), 1012–1020. doi:10.1093/schbul/sbr006
   PubMed Web of Science ®Google Scholar
• Tadori, Y., Forbes, R. A., McQuade, R. D., & Kikuchi, T. (2011). Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors. European Journal of Pharmacology, 666(1-3), 43–52. doi:10.1016/j.ejphar.2011.05.050
   PubMed Web of Science ®Google Scholar
• Tadori, Y., Forbes, R. A., McQuade, R. D., & Kikuchi, T. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European Journal of Pharmacology, 668(3), 355–365. doi:10.1016/j.ejphar.2011.07.020
   PubMed Web of Science ®Google Scholar
• Taipale, H., Solmi, M., Lähteenvuo, M., Tanskanen, A., Correll, C. U., & Tiihonen, J. (2021). Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. The Lancet. Psychiatry, 8(10), 883–891. doi:10.1016/S2215-0366(21)00241-8
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Thiyanavadivel, S., Agid, O., & Remington, G. (2018). Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 193, 29–36. doi:10.1016/j.schres.2017.08.012
   PubMed Web of Science ®Google Scholar
• Tandon, R., & Jibson, M. D. (2002). Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Annals of Clinical Psychiatry : official Journal of the American Academy of Clinical Psychiatrists, 14(2), 123–129. doi:10.3109/10401230209149099
   PubMedGoogle Scholar
• Taylor, D. M., Young, A., & Barnes, T. R. E. (2021). The Maudsley Prescribing Guidelines in Psychiatry., 14th Edition. Hoboken, NJ: Wiley Blackwell.
   Google Scholar
• Taylor, D., Hanssens, L., Loze, J. Y., Pans, M., L'Italien, G., & Marcus, R. N. (2008). Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry : The Journal of the Association of European Psychiatrists, 23(5), 336–343. 8/2008doi:10.1016/j.eurpsy.2008.03.006
   PubMed Web of Science ®Google Scholar
• Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Björkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015). Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin, 41(3), 656–663. Maydoi:10.1093/schbul/sbu164
   PubMed Web of Science ®Google Scholar
• Tost, H., Alam, T., & Meyer-Lindenberg, A. (2010). Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neuroscience and Biobehavioral Reviews, 34(5), 689–700. doi:10.1016/j.neubiorev.2009.06.005
   PubMed Web of Science ®Google Scholar
• Touafchia, D., Montastruc, F., Lapeyre-Mestre, M., Rousseau, V., Chebane, L., & Revet, A. (2020). Drug-induced tics: An observational postmarketing study. Human Psychopharmacology, 35(4), e2734. doi:10.1002/hup.2734
   PubMed Web of Science ®Google Scholar
• Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017). Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychological Medicine, 47(13), 2217–2228. doi:10.1017/S0033291717000873
   PubMed Web of Science ®Google Scholar
• Wadenberg, M.-L. G. (2007). Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors. Future Neurology, 2(2), 153–165. 2007/03/01doi:10.2217/14796708.2.2.153
   Google Scholar
• Wang, L. J., Ree, S. C., Huang, Y. S., Hsiao, C. C., & Chen, C. K. (2013). Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 40, 260–266. doi:10.1016/j.pnpbp.2012.10.010
   PubMed Web of Science ®Google Scholar
• Xiang, J., Xu, N., Wang, X., Li, S., Yu, Q., Liang, M., Nan, F., Shu, S., Yan, R., Zhu, Y., & Liao, L. (2021). Bioequivalence of 2 Aripiprazole Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development, 10(8), 840–849. doi:10.1002/cpdd.954
   PubMed Web of Science ®Google Scholar
• Yin, J., Barr, A. M., Ramos-Miguel, A., & Procyshyn, R. M. (2017). Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Current Neuropharmacology, 15(1), 174–183. doi:10.2174/1570159x14666160606093602
   PubMed Web of Science ®Google Scholar
• Yoshida, K., & Takeuchi, H. (2021). Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behavioural Brain Research, 402, 113098. doi:10.1016/j.bbr.2020.113098
   PubMed Web of Science ®Google Scholar
• Zhao, J., Song, X., Ai, X., Gu, X., Huang, G., Li, X., Pang, L., Ding, M., Ding, S., & Lv, L. (2015). Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: an 8-Week Randomized, Open-Label, Comparative Clinical Trial. PLoS One, 10(10), e0139717. doi:10.1371/journal.pone.0139717
   PubMed Web of Science ®Google Scholar
• Zimbroff, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry, 154(6), 782–791.
   PubMed Web of Science ®Google Scholar